Viewing Study NCT05844735


Ignite Creation Date: 2025-12-24 @ 10:36 PM
Ignite Modification Date: 2025-12-24 @ 10:36 PM
Study NCT ID: NCT05844735
Status: COMPLETED
Last Update Posted: 2025-09-16
First Post: 2023-04-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
Sponsor: Sanofi
Organization:

Study Overview

Official Title: A Two-part, Randomized Partially-blinded, Parallelgroup, Placebo- and Active Comparatorcontrolled Phase 1 Study to Evaluate the Photosafety of Repeated Oral Dose of SAR441566 in Healthy Adult Participants
Status: COMPLETED
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age.

There will be two parts:

* Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo.
* Part II is an open label arm consisting of participants treated with ciprofloxacin which induces mild phototoxicity and serves as a positive control.
Detailed Description: The overall duration of the study for each participant will be up to approximately 48 days

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
U1111-1255-5054 REGISTRY ICTRP View